PLRX - Pliant Therapeutics Inc Stock Price, Fair Value and News

$1.53+0.04 (+2.68%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PLRX Price Action

Last 7 days

-3.2%

Last 30 days

-8.4%

Last 90 days

-6.1%

Trailing 12 Months

-89.5%

PLRX RSI Chart

PLRX Valuation

Market Cap

94.0M

Price/Earnings (Trailing)

-0.54

Price/Sales (Trailing)

59.12

Price/Free Cashflow

-0.59

PLRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PLRX Fundamentals

PLRX Revenue

Revenue (TTM)

1.6M

PLRX Earnings

Earnings (TTM)

-175.5M

Earnings Growth (Yr)

54.47%

Earnings Growth (Qtr)

39.26%

PLRX Profitability

Return on Equity

-87.62%

Return on Assets

-63.45%

Free Cashflow Yield

-168.9%

PLRX Investor Care

Shares Dilution (1Y)

0.98%

Diluted EPS (TTM)

-2.87

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.8M	5.0M	3.5M	1.6M
2022	6.6M	9.8M	9.7M	9.7M
2021	15.0M	13.2M	10.0M	7.6M
2020	53.2M	49.4M	45.6M	41.8M
2019	0	0	0	57.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avÃƒÆ’Ã…Â¸6 and avÃƒÆ’Ã…Â¸1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avÃƒÆ’Ã…Â¸1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avÃƒÆ’Ã…Â¸8 and avÃƒÆ’Ã…Â¸1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO	Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
WEBSITE	https://pliantrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	155

Pliant Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Pliant Therapeutics Inc? What does PLRX stand for in stocks?

PLRX is the stock ticker symbol of Pliant Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pliant Therapeutics Inc (PLRX)?

As of Wed Dec 03 2025, market cap of Pliant Therapeutics Inc is 94.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers.

Is Pliant Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLRX is over valued or under valued. Whether Pliant Therapeutics Inc is cheap or expensive depends on the assumptions which impact Pliant Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLRX.

What is Pliant Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, PLRX's PE ratio (Price to Earnings) is -0.54 and Price to Sales (PS) ratio is 59.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLRX PE ratio will change depending on the future growth rate expectations of investors.